6,322 results
Search Results
102. Editorial: Muscles at the expense of liver injury. Is it worth it?
103. Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply.
104. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed. Authors' reply.
105. Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease—authors' reply.
106. Editorial: Corticosteroids for severe checkpoint inhibitor‐induced liver injury—Not one size fits all?
107. Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight—Authors' reply.
108. Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world.
109. Letter: Association of polymorphic variant of SerpinB3 and faster cirrhosis decompensation in patients with cirrhosis—More evidence needed.
110. Letter: Switching to tenofovir alafenamide for nucleos(t)ide analogue‐experienced patients with chronic hepatitis B can increase body weight.
111. Editorial: Shorter course of intravenous terlipressin in acute variceal bleeding—the promise, controversies and future directions. Author's reply.
112. Editorial: Liver elastography for chronic hepatitis D—the end of liver biopsy?
113. Editorial: Shorter course of intravenous terlipressin in acute variceal bleeding ‐ the promise, controversies and future directions.
114. Letter: Severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels—authors' reply.
115. Letter: Severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels.
116. Editorial: Towards optimal thiopurine therapy for inflammatory bowel disease.
117. Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States.
118. Letter: Should ulcerative colitis be monitored more or less invasively? Authors' reply.
119. Letter: The multifaceted role of Escherichia coli in influencing disorders of the industrial populations—Authors' reply.
120. Editorial: The prevalence and outcomes of perianal Crohn's disease across the treatment eras—Authors' reply.
121. Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index (DASI) in predicting mortality and guiding prehabilitation. Authors' reply.
122. Letter: Should ulcerative colitis be monitored more or less invasively?
123. Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests? Authors' reply.
124. Letter: The multifaceted role of Escherichia coli in influencing disorders of industrial populations.
125. Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras.
126. Editorial: Enhancing frailty assessment in liver transplantation candidates—The role of the Duke Activity Status Index in predicting mortality and guiding prehabilitation.
127. Editorial: How often can we get the right diagnosis after bone marrow transplant in patients with abnormal liver function tests?
128. Editorial: co‐morbid gastrointestinal conditions are an important consideration in IBS management—authors' reply.
129. Plasma and breast milk pharmacokinetics of tenofovir alafenamide in mothers with chronic hepatitis B infection.
130. Letter: sex disparities in presentation and prognosis of 1110 patients with hepatocellular carcinoma.
131. Editorial: risk of gastric and duodenal ulcers among new users of low‐dose aspirin.
132. Editorial: STAT3 phosphorylation for tofacitinib monitoring in ulcerative colitis—a step towards precision medicine?
133. Letter: association of circulating bile acid concentrations and non‐alcoholic fatty liver disease.
134. Editorial: it's time to standardise competencies in intestinal ultrasound.
135. Letter: normalizing the ileoanal pouch—more than a one‐step technique. Authors' reply.
136. Letter: normalising the ileoanal pouch—more than a one‐step technique.
137. Editorial: estimating the costs of care in irritable bowel syndrome—a necessary step to enhance value‐based care for a high‐prevalence, low‐cost condition. Authors' reply.
138. Editorial: estimating the costs of care in irritable bowel syndrome—a necessary step to enhance value‐based care for a high‐prevalence, low‐cost condition.
139. Letter: paying attention to the comorbidities or extraintestinal complications in patients with inflammatory bowel disease during the COVID‐19 pandemic.
140. Editorial: safety in numbers—cycling of biologics does not increase risk of adverse outcomes.
141. Editorial: what is normal function of a pelvic pouch? Authors' reply.
142. Editorial: liver and kidney injury from remdesivir—an issue not as much as its purpose. Authors' reply.
143. Editorial: what is normal function of a pelvic pouch?
144. Letter: the effect of anti‐COVID‐19 treatment on the outcome of patients with inflammatory bowel disease.
145. Editorial: histologic normalisation in ulcerative colitis.
146. Letter: childhood recurrent abdominal pain is associated with increased duodenal eosinophilia independent of Helicobacter pylori infection.
147. Discussion of paper by van Deventer & Camoglio.
148. Systematic review: health-related quality of life in children and adults with eosinophilic oesophagitis-instruments for measurement and determinant factors.
149. Systematic review: interventions for abdominal pain management in inflammatory bowel disease.
150. TIPSS and reversal of sarcopenia, and TIPSS is a promising therapy for sarcopenia in cirrhosis—Authors' reply.
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.